Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: A review by a Central European Consensus Panel

Wiener Klinische Wochenschrift

Volumn 122, Issue 11-12, 2010, Pages 368-379

  Steger, Guenther G ^a   Abrahámová, Jitka ^b   Bacanu, Florin ^c   Brincat, Stephen ^d   Brize, Arija ^e   Česas, Alvydas ^f   Čufer, Tanja ^g   Dank, Magdolna ^h   Duchnowska, Renata ⁱ   Eniu, Alexandru ^j   Jassem, Jacek ^k   Kahán, Zsuzsanna ^l   Matos, Erika ^m   Padrik, Peeter ⁿ   Plāte, Signe ^e   Pokker, Helis ^o   Purkalne, Gunta ^p   Timcheva, Constanta ^q   Tzekova, Valentina ^r   Vyzula, Rostislav ^s   Zielinski, Christoph C ^a   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^c Sfanta Maria Clinical Hospital   (Romania)

^d Sir Paul Boffa Hospital   (Malta)

^e RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^f Klaipedos Universitetine Ligonine   (Lithuania)

^g Univerzitetna Klinika Golnik   (Slovenia)

^h SEMMELWEIS UNIVERSITY   (Hungary)

ⁱ MILITARY INSTITUTE OF MEDICINE   (Poland)

^j THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^k MEDICAL UNIVERSITY OF GDANSK   (Poland)

^l Onkotherápiás Klinika   (Hungary)

^m INSTITUTE OF ONCOLOGY   (Slovenia)

ⁿ TARTU UNIVERSITY CLINICS   (Estonia)

^o Keemiaravi Osakond   (Estonia)

^p PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^q Specializirana Bolnica Za Aktivno Lechenie Po Onkologia   (Bulgaria)

^r Klinika Po Chimioterapia   (Bulgaria)

^s MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EXEMESTANE; FULVESTRANT; LAPATINIB; LETROZOLE; PACLITAXEL; PROTEIN TYROSINE KINASE; TAMOXIFEN; TRASTUZUMAB;

ALOPECIA; ANOREXIA; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; METASTASIS; NAUSEA; NEUROPATHY; NEUTROPENIA; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PRURITUS; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 77954614850     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-010-1373-6     Document Type: Conference Paper

References (69)

1. J Ferlay P Autier M Boniol M Heanue M Colombet P Boyle 2007 Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 581 592 10.1093/annonc/mdl498 1:STN:280:DC%2BD2s7hslSgtw%3D%3D 17287242 (Pubitemid 46359643)
2. A Jemal RC Tiwari T Murray A Ghafoor A Samuels E Ward EJ Feuer MJ Thun American Cancer Society 2004 Cancer statistics, 2004 CA Cancer J Clin 54 8 29 10.3322/canjclin.54.1.8 14974761
3. Phan AT, Hennessy BT, Valero V (2006) Metastatic breast cancer. In: Kantarjian HM, Wolff RA, Koller CA (eds) MD Anderson manual of medical oncology. McGraw-Hill, New York, pp 503-26
4. F Andre K Slimane T Bachelot A Dunant M Namer A Barrelier O Kabbaj JP Spano H Marsiglia R Rouzier S Delaloge M Spielmann 2004 Breast cancer with synchronous metastases: trends in survival during a 14-year period J Clin Oncol 22 3302 3308 10.1200/JCO.2004.08.095 15310773 (Pubitemid 41103686)
5. SK Chia CH Speers Y D'yachkova A Kang S Malfair-Taylor J Barnett A Coldman KA Gelmon SE O'reilly IA Olivotto 2007 The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer Cancer 110 973 979 10.1002/cncr.22867 17647245 (Pubitemid 47312861)
6. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D 3798106
7. DJ Slamon W Godolphin LA Jones JA Holt SG Wong DE Keith WJ Levin SG Stuart J Udove A Ullrich MF Press 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712 10.1126/science.2470152 1:STN:280:DyaL1M3kt1Wntg%3D%3D 2470152
8. LM Bender R Nahta 2008 Her2 cross talk and therapeutic resistance in breast cancer Front Biosci 13 3906 3912 10.2741/2978 1:CAS:528: DC%2BD1cXnsVKqtbY%3D 18508484 (Pubitemid 351594668)
9. G Atalay F Cardoso A Awada MJ Piccart 2003 Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer Ann Oncol 14 1346 1363 10.1093/annonc/mdg365 1:STN:280:DC%2BD3svhsV2qtQ%3D%3D 12954573 (Pubitemid 37185280)
10. Y Yarden MX Sliwkowski 2001 Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 127 137 10.1038/35052073 1:CAS:528:DC%2BD3MXivVWnt7k%3D 11252954 (Pubitemid 33674041)
11. T Kuukasjärvi J Kononen H Helin K Holli J Isola 1996 Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy J Clin Oncol 14 2584 2589 8823339
12. V Guarneri S Giovannelli G Ficarra S Bettelli A Maiorana F Piacentini E Barbieri MV Dieci R D'Amico G Jovic P Conte 2008 Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management Oncologist 13 8 838 844 10.1634/theoncologist.2008-0048 1:CAS:528:DC%2BD1cXhtF2qs7vP 18650259
13. SH Giordano AU Buzdar TL Smith SW Kau Y Yang GN Hortobagyi 2004 Is breast cancer survival improving? Cancer 100 44 52 10.1002/cncr.11859 14692023 (Pubitemid 37553538)
14. S Beslija J Bonneterre H Burstein V Cocquyt M Gnant P Goodwin V Heinemann J Jassem WJ Köstler M Krainer S Menard T Petit L Petruzelka K Possinger P Schmid E Stadtmauer M Stockler S Van Belle C Vogel N Wilcken C Wiltschke CC Zielinski H Zwierzina 2007 Second consensus on medical treatment of metastatic breast cancer Ann Oncol 18 2 215 225 10.1093/annonc/mdl155 1:STN:280: DC%2BD2s7ptFCkug%3D%3D 16831851 (Pubitemid 46323085)
15. AK Conlin AD Seidman 2007 Taxanes in breast cancer: an update Curr Oncol Rep 9 22 30 10.1007/BF02951422 1:CAS:528:DC%2BD2sXpt1Grur4%3D 17164044
16. WH Frishman HM Sung HC Yee LL Liu AI Einzig J Dutcher D Keefe 1996 Cardiovascular toxicity with cancer chemotherapy Curr Probl Cardiol 21 225 286 10.1016/S0146-2806(96)80011-9 1:STN:280:DyaK283ot1answ%3D%3D 8697798
17. M Marty 2001 Liposomal doxorubicin (Myocet) and conventional anthracyclines: a comparison Breast 10 Suppl 2 28 33 10.1016/S0960-9776(01) 80005-9
18. C Bernard-Marty F Cardoso MJ Piccart 2004 Facts and controversies in systemic treatment of metastatic breast cancer Oncologist 9 617 632 10.1634/theoncologist.9-6-617 15561806 (Pubitemid 39546403)
19. Carrick S, Parker S, Wilcken N, Ghersi D, Marzo M, Simes J (2005) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev: CD003372
20. R Fossati C Confalonieri V Torri E Ghislandi A Penna V Pistotti A Tinazzi A Liberati 1998 Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women J Clin Oncol 16 3439 3460 1:CAS:528:DyaK1cXmvFGrurs%3D 9779724
21. D Mauri NP Polyzos G Salanti N Pavlidis JP Ioannidis 2008 Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer J Natl Cancer Inst 100 1780 1791 10.1093/jnci/djn414 1:CAS:528:DC%2BD1MXhtVGksA%3D%3D 19066278
22. Wilcken N, Hornbuckle J, Ghersi D (2003) Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev: CD002747
23. KT Flaherty MS Brose 2006 Her-2 targeted therapy: beyond breast cancer and trastuzumab Curr Oncol Rep 8 90 95 10.1007/s11912-006-0042-4 1:CAS:528:DC%2BD28Xis1yiu7w%3D 16507217
24. Y Madarnas M Trudeau JA Franek D McCready KI Pritchard H Messersmith 2008 Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review Cancer Treat Rev 34 539 557 10.1016/j.ctrv.2008.03.013 1:CAS:528:DC%2BD1cXhtV2is7%2FL 18502589
25. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 10.1056/NEJM200103153441101 1:CAS:528: DC%2BD3MXisVGktrc%3D 11248153 (Pubitemid 32222155)
26. M Marty F Cognetti D Maraninchi R Snyder L Mauriac M Tubiana-Hulin S Chan D Grimes A Antón A Lluch J Kennedy K O'Byrne P Conte M Green C Ward K Mayne JM Extra 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with HER2-positive metastatic breast cancer administered as first line treatment: the M77001 study group J Clin Oncol 23 4265 4274 10.1200/JCO.2005.04.173 1:CAS:528:DC%2BD2MXms12gs70%3D 15911866 (Pubitemid 46207001)
27. Von Minckwitz G, Zielinski C, Maarteense E, Vogel P, Schmidt M, Eidtmann H, Cufer T, de Jongh FE, Kaufmann M, Loibl S (2008) Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05). J Clin Oncol 26[May 20 Suppl]: Abstract No. 1025
28. Mackey JR, Kaufman B, Clemens M, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Jones A (2006) Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer (MBC). Presented at the European Society for Medical Oncology (ESMO) Congress 2006: Abstract LBA2
29. M Guglin R Cutro JD Mishkin 2008 Trastuzumab-induced cardiomyopathy J Card Fail 14 437 444 10.1016/j.cardfail.2008.02.002 1:CAS:528: DC%2BD1cXms1WksrY%3D 18514938 (Pubitemid 351749842)
30. F Petrelli M Cabiddu ME Cazzaniga M Cremonesi S Barni 2008 Targeted therapies for the treatment of breast cancer in the post-trastuzumab era Oncologist 13 4 373 381 10.1634/theoncologist.2007-0173 1:CAS:528: DC%2BD1cXmslKksLc%3D 18448551 (Pubitemid 351679916)
31. A Seidman C Hudis MK Pierri S Shak V Paton M Ashby M Murphy SJ Stewart D Keefe 2002 Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 1215 1221 10.1200/JCO.20.5.1215 1:CAS:528:DC%2BD38XisVWmuro%3D 11870163 (Pubitemid 34177427)
32. Y Lu X Zi M Pollak 2004 Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells Int J Cancer 108 334 341 10.1002/ijc.11445 1:CAS:528:DC%2BD3sXhtVSmu7fI 14648698 (Pubitemid 37549597)
33. R Nahta T Takahashi NT Ueno MC Hung FJ Esteva 2004 P27 (kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells Cancer Res 64 3981 3986 10.1158/0008-5472.CAN-03-3900 1:CAS:528: DC%2BD2cXksVKns7k%3D 15173011 (Pubitemid 38697313)
34. R Nahta LX Yuan B Zhang R Kobayashi FJ Esteva 2005 Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells Cancer Res 65 11118 11128 10.1158/0008-5472.CAN-04-3841 1:CAS:528:DC%2BD2MXht1KjsrrI 16322262 (Pubitemid 41713383)
35. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NE Davidson 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D 18160686
36. Miles D, Chan A, Romieu G, Dirix LY, Cortes JA, Pivot P, Tomczak T, Taran T, Harbeck N, Steger GG (2008) Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26[May 20 Suppl]: Abstract LBA1011
37. T Pawson 2002 Regulation and targets of receptor tyrosine kinases Eur J Cancer 38 Suppl 5 S3 10 10.1016/S0959-8049(02)80597-4 12528767
38. MH Nelson CR Dolder 2007 A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer Ther Clin Risk Manag 3 665 673 1:CAS:528:DC%2BD2sXhtFyjtL%2FO 18472989
39. DW Rusnak K Lackey K Affleck ER Wood KJ Alligood N Rhodes BR Keith DM Murray WB Knight RJ Mullin TM Gilmer 2001 The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo Mol Cancer Ther 1 85 94 1:CAS:528:DC%2BD38XlsFSmtbs%3D 12467226
40. W Xia RJ Mullin BR Keith LH Liu H Ma DW Rusnak G Owens KJ Alligood NL Spector 2002 Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/HER2/Neu and downstream Erk1/2 and AKT pathways Oncogene 21 6255 6263 10.1038/sj.onc.1205794 1:CAS:528:DC%2BD38Xms1yrs7w%3D 12214266
41. GE Konecny MD Pegram N Venkatesan R Finn G Yang M Rahmeh M Untch DW Rusnak G Spehar RJ Mullin BR Keith TM Gilmer M Berger KC Podratz DJ Slamon 2006 Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer Res 66 1630 1639 10.1158/0008-5472.CAN-05-1182 1:CAS:528:DC%2BD28XpsVemsg%3D%3D 16452222 (Pubitemid 43259947)
42. R Nahta LX Yuan Y Du FJ Esteva 2007 Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling Mol Cancer Ther 6 667 674 10.1158/1535-7163.MCT-06-0423 1:CAS:528:DC%2BD2sXhvVWrsbc%3D 17308062 (Pubitemid 46332467)
43. HA Burris 3rd HI Hurwitz EC Dees A Dowlati KL Blackwell B O'Neil PK Marcom MJ Ellis B Overmoyer SF Jones JL Harris DA Smith KM Koch A Stead S Mangum NL Spector 2005 Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas J Clin Oncol 23 5305 5313 10.1200/JCO.2005.16.584 1:CAS:528:DC%2BD2MXpslOrtL0%3D 15955900 (Pubitemid 46206984)
44. Blackwell KL, Kaplan EH, Franco SX, Marcom PK, Maleski JE, Sorensen MJ, Berger MS (2004) A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 22[Suppl 14]: Abstract No. 3006
45. Blackwell KL, Burstein H, Pegram M, Storniolo AM, Salazar VM, Maleski JE, Lin X, Spector N, Stein SH, Berger MS (2005) Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. J Clin Oncol 23[Suppl 16]: Abstract No. 3004
46. H Burstein A Storniolo S Franco VM Salazar MS Sorenson SH Stein 2004 A phase II, open-label, multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens Ann Oncol 15 Suppl 3 27 Abstract No. 1040
47. HL Gomez DC Doval MA Chavez PC Ang Z Aziz S Nag C Ng SX Franco LW Chow MC Arbushites MA Casey MS Berger SH Stein GW Sledge 2008 Efficacy and safety of Lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer J Clin Oncol 26 2999 3005 10.1200/JCO.2007.14.0590 1:CAS:528:DC%2BD1cXoslOqsLo%3D 18458039
48. N Reddy R Cohen B Whitehead KM Koch A Stead AP Beelen LD Lewis 2007 A phase I, open-label, three period, randomized crossover study to evaluate the effect of food on the pharmacokinetics of lapatinib in cancer patients Clin Pharmacol Ther 81 16 17 10.1038/sj.clpt.6100013 (Pubitemid 46050876)
49. A Di Leo H Gomez Z Aziz Z Zvirbule J Bines MC Arbushites SF Guerrera M Koehler C Oliva SH Stein LS Williams J Dering RS Finn MF Press 2008 Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer J Clin Oncol 26 5544 5552 10.1200/JCO.2008.16.2578 1:CAS:528:DC%2BD1MXmsVSktA%3D%3D 18955454
50. Jagiello-Gruszfeld A, Tjulandin S, Dobrovolskaya N, Manikhas A, Pienkowski T, Knott A, DeSilvio M, Oliva C (2008) Lapatinib (L) with weekly Paclitaxel (P) as first-line therapy for patients (pts) with ErbB2+ Metastatic Breast Cancer (MBC). Poster No. 4135, presented at the San Antonio Breast Cancer Symposium 2008
51. S Johnston M Pegram M Press J Pippen X Pivot H Gomez A Florance L O'Rourke J Maltzman 2009 Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 trial Cancer Res 69 Suppl 2 74s Abstract No. 46
52. CE Geyer J Forster D Lindquist S Chan CG Romieu T Pienkowski A Jagiello-Gruszfeld J Crown A Chan B Kaufman D Skarlos M Campone N Davidson M Berger C Oliva SD Rubin S Stein D Cameron 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743 10.1056/NEJMoa064320 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D 17192538 (Pubitemid 46021510)
53. D Cameron M Casey M Press D Lindquist T Pienkowski CG Romieu S Chan A Jagiello-Gruszfeld B Kaufman J Crown A Chan M Campone P Viens N Davidson V Gorbounova JI Raats D Skarlos B Newstat D Roychowdhury P Paoletti C Oliva S Rubin S Stein CE Geyer 2008 A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses Breast Cancer Res Treat 112 533 543 10.1007/s10549-007-9885-0 1:CAS:528: DC%2BD1cXhtl2mu7bI 18188694
54. Zhou X, Segreti A, Cameron D, Geyer CE, Cella D, Amonkar M, Stein S, Walker MD (2008) Effect of lapatinib plus capecitabine (L+C) on quality of life (QOL) compared to capecitabine (C) alone in HER2/Neu + metastatic breast cancer (MBC): an exploratory analysis. J Clin Oncol 26[May 20 Suppl]: Abstract No. 9532
55. NU Lin JR Bellon EP Winer 2004 CNS metastases in breast cancer J Clin Oncol 22 3608 3617 10.1200/JCO.2004.01.175 15337811 (Pubitemid 41103668)
56. JC Bendell SM Domchek HJ Burstein L Harris J Younger I Kuter C Bunnell M Rue R Gelman E Winer 2003 Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma Cancer 97 2972 2977 10.1002/cncr.11436 12784331 (Pubitemid 36676250)
57. AJ Clayton S Danson S Jolly WD Ryder PA Burt AL Stewart PM Wilkinson RS Welch B Magee G Wilson A Howell AM Wardley 2004 Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer Br J Cancer 91 639 643 1:CAS:528:DC%2BD2cXmsVCgs7k%3D 15266327
58. NU Lin LA Carey MC Liu J Younger SE Come M Ewend GJ Harris E Bullitt AD Van den Abbeele JW Henson X Li R Gelman HJ Burstein E Kasparian DG Kirsch A Crawford F Hochberg EP Winer 2008 Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 26 1993 1999 10.1200/JCO.2007.12.3588 1:CAS:528:DC%2BD1cXlvFaqs7o%3D 18421051
59. O'Shaughnessy J, Blackwell KL, Burstein H, Storniolo AM, Sledge G, Baselga J, Koehler M, Laabs S, Florance A, Roychowdhury D (2008) A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 26[Suppl]: Abstract No. 1015
60. Rugo HS, Franco S, Munster P, Stopeck A, Ma W, Lyandres J, Lahiri S, Arbushites M, Koehler M, Dickler MN (2008) A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC). J Clin Oncol 26[May 20 Suppl]: Abstract No. 1042
61. A Mukherjee AS Dhadda M Shehata S Chan 2007 Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer Exp Opin Pharmacother 8 2189 2204 10.1517/14656566.8.13.2189 1:CAS:528:DC%2BD2sXpsFSgt7g%3D Erratum in: Exp Opin Pharmacother 2007; 8: 3085 (Pubitemid 47505592)
62. B Moy JD Maltzman PE Goss 2007 Phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with HER2/Neu-overexpressing breast cancer: Tykerb evaluation after chemotherapy (TEACH) study Breast 16 Suppl 1 S47 10.1016/S0960-9776(07)70179-0 Abstract P119
63. MJ Piccart-Gebhart EA Perez J Baselga RD Gelber D Rosa E Azambuja C Oliva A Goldhirsch 2007 ALTTO (adjuvant lapatinib and/or trastuzumab treatment optimisation) study [BIG 206/N063D/EGF106708]: a phase III study for HER2-overexpressing early breast cancer (BC) Breast 16 Suppl 1 S46 10.1016/S0960-9776(07)70178-9 Abstract P118
64. J Baselga MJ Piccart-Gebhart RD Gelber S Di Cosimo G Viale M Koehler F Rojo 2007 neo-ALTTO (neoadjuvant lapatinib and/or trastuzumab treatment optimisation) study [BIG 106/SOLTI/EGF106903]: a phase III translational study for Her2-overexpressing early breast cancer (BC) Breast 16 Suppl 1 S48 10.1016/S0960-9776(07)70184-4 Abstract P124
65. RS Tuma 2007 Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials J Natl Cancer Inst 99 348 349 10.1093/jnci/djk122 17341725
66. Kaufman B, Trudeau ME, Johnston S, Awada A, Blackwell KL, Bachelot T, Salazar V, Westlund R, DeSilvio M, Zaks T (2008) Clinical activity of lapatinib monotherapy in patients with HER2+ relapsed/refractory inflammatory breast cancer (IBC): Final results of the expanded HER2+ cohort in EGF103009. J Clin Oncol 26[May 20 Suppl]: Abstract No. 636
67. EA Perez M Koehler J Byrne AJ Preston E Rappold MS Ewer 2008 Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials Mayo Clin Proc 83 679 686 10.4065/83.6.679 18533085 (Pubitemid 351810568)
68. JP Crown HA Burris 3rd F Boyle S Jones M Koehler BO Newstat R Parikh C Oliva A Preston J Byrne S Chan 2008 Pooled analysis of diarrhea events in patients with cancer treated with lapatinib Breast Cancer Res Treat 112 317 325 10.1007/s10549-007-9860-9 1:CAS:528:DC%2BD1cXht1Cms73P 18204897
69. K Bullock K Blackwell 2008 Clinical efficacy of Taxane-Trastuzumab combination regimens for HER-2-positive metastatic breast cancer Oncologist 13 515 525 10.1634/theoncologist.2007-0204 1:CAS:528:DC%2BD1cXotFait7o%3D 18515736 (Pubitemid 351872869)